RS61072B1 - Sistemi aditiva za upotrebu u pegilaciji proteina - Google Patents
Sistemi aditiva za upotrebu u pegilaciji proteinaInfo
- Publication number
- RS61072B1 RS61072B1 RS20201382A RSP20201382A RS61072B1 RS 61072 B1 RS61072 B1 RS 61072B1 RS 20201382 A RS20201382 A RS 20201382A RS P20201382 A RSP20201382 A RS P20201382A RS 61072 B1 RS61072 B1 RS 61072B1
- Authority
- RS
- Serbia
- Prior art keywords
- peg
- reaction
- protein
- equiv
- additive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/64—Relaxins
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562258644P | 2015-11-23 | 2015-11-23 | |
| EP16816042.2A EP3380487B1 (en) | 2015-11-23 | 2016-11-22 | Additive systems for use in protein pegylation |
| PCT/US2016/063313 WO2017091568A1 (en) | 2015-11-23 | 2016-11-22 | Additive systems for use in protein pegylation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS61072B1 true RS61072B1 (sr) | 2020-12-31 |
Family
ID=57589163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20201382A RS61072B1 (sr) | 2015-11-23 | 2016-11-22 | Sistemi aditiva za upotrebu u pegilaciji proteina |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10617765B2 (enExample) |
| EP (2) | EP3789395B1 (enExample) |
| JP (2) | JP6921821B2 (enExample) |
| KR (1) | KR102688003B1 (enExample) |
| CN (2) | CN115819494A (enExample) |
| CY (1) | CY1123699T1 (enExample) |
| DK (1) | DK3380487T3 (enExample) |
| ES (1) | ES2827776T3 (enExample) |
| HR (1) | HRP20201832T1 (enExample) |
| HU (1) | HUE052634T2 (enExample) |
| LT (1) | LT3380487T (enExample) |
| PL (1) | PL3380487T3 (enExample) |
| PT (1) | PT3380487T (enExample) |
| RS (1) | RS61072B1 (enExample) |
| SI (1) | SI3380487T1 (enExample) |
| SM (1) | SMT202000649T1 (enExample) |
| WO (1) | WO2017091568A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3380487T1 (sl) * | 2015-11-23 | 2020-11-30 | Bristol-Myers Squibb Company | Sistemi dodatkov za uporabo pri pegilaciji proteinov |
| JP7441826B2 (ja) * | 2018-09-11 | 2024-03-01 | アンブルックス，インコーポレイテッド | インターロイキン－２ポリペプチド抱合物およびその使用 |
| CN111484551B (zh) * | 2020-03-19 | 2022-02-11 | 北京翼方生物科技有限责任公司 | 一种聚乙二醇修饰的重组人碱性成纤维细胞生长因子 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19535571A1 (de) | 1995-09-14 | 1997-03-20 | Boehringer Mannheim Gmbh | Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten |
| TW518219B (en) | 1996-04-26 | 2003-01-21 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
| EP0885613A1 (de) | 1997-06-21 | 1998-12-23 | Roche Diagnostics GmbH | Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin |
| DE19734293A1 (de) | 1997-08-08 | 1999-02-11 | Boehringer Mannheim Gmbh | Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen |
| JP5460958B2 (ja) * | 2004-03-17 | 2014-04-02 | アンチキャンサー インコーポレーテッド | タンパク質ポリエチレングリコール（ｐｅｇ）複合体形成を増大させる方法 |
| EP1885404A2 (en) * | 2005-06-01 | 2008-02-13 | Alza Corporation | Bioconjugation reactions for acylating polyethlene glycol reagents |
| HRP20110404T1 (hr) | 2005-11-08 | 2011-08-31 | Ambrx | Ubrzivači za modifikaciju ne-prirodnih aminokiselina i polipeptida ne-prirodnih aminokiselina |
| KR20140012199A (ko) * | 2007-03-30 | 2014-01-29 | 암브룩스, 인코포레이티드 | 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도 |
| JP6508781B2 (ja) | 2013-01-30 | 2019-05-08 | アベラス バイオサイエンシーズ，インク． | 選択的な送達分子及びその使用方法 |
| US20160082119A1 (en) | 2013-04-22 | 2016-03-24 | Avelas Biosciences, Inc. | Selective drug delivery compositions and methods of use |
| CN107108710B (zh) | 2014-10-24 | 2022-02-15 | 百时美施贵宝公司 | 修饰的fgf-21多肽及其用途 |
| SI3380487T1 (sl) * | 2015-11-23 | 2020-11-30 | Bristol-Myers Squibb Company | Sistemi dodatkov za uporabo pri pegilaciji proteinov |
-
2016
- 2016-11-22 SI SI201630957T patent/SI3380487T1/sl unknown
- 2016-11-22 LT LTEP16816042.2T patent/LT3380487T/lt unknown
- 2016-11-22 WO PCT/US2016/063313 patent/WO2017091568A1/en not_active Ceased
- 2016-11-22 HU HUE16816042A patent/HUE052634T2/hu unknown
- 2016-11-22 JP JP2018526713A patent/JP6921821B2/ja active Active
- 2016-11-22 CN CN202211743414.4A patent/CN115819494A/zh active Pending
- 2016-11-22 DK DK16816042.2T patent/DK3380487T3/da active
- 2016-11-22 PL PL16816042T patent/PL3380487T3/pl unknown
- 2016-11-22 RS RS20201382A patent/RS61072B1/sr unknown
- 2016-11-22 KR KR1020187017508A patent/KR102688003B1/ko active Active
- 2016-11-22 PT PT168160422T patent/PT3380487T/pt unknown
- 2016-11-22 EP EP20189107.4A patent/EP3789395B1/en active Active
- 2016-11-22 CN CN201680067897.7A patent/CN108350025B/zh active Active
- 2016-11-22 ES ES16816042T patent/ES2827776T3/es active Active
- 2016-11-22 SM SM20200649T patent/SMT202000649T1/it unknown
- 2016-11-22 HR HRP20201832TT patent/HRP20201832T1/hr unknown
- 2016-11-22 EP EP16816042.2A patent/EP3380487B1/en active Active
- 2016-11-22 US US15/776,923 patent/US10617765B2/en active Active
-
2020
- 2020-02-21 US US16/797,361 patent/US11213589B2/en active Active
- 2020-11-20 CY CY20201101102T patent/CY1123699T1/el unknown
-
2021
- 2021-07-28 JP JP2021123154A patent/JP7257457B2/ja active Active
- 2021-12-03 US US17/541,636 patent/US20220160883A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6921821B2 (ja) | 2021-08-18 |
| US20200276319A1 (en) | 2020-09-03 |
| SI3380487T1 (sl) | 2020-11-30 |
| WO2017091568A8 (en) | 2018-01-04 |
| JP2021176890A (ja) | 2021-11-11 |
| CN115819494A (zh) | 2023-03-21 |
| CY1123699T1 (el) | 2022-03-24 |
| JP7257457B2 (ja) | 2023-04-13 |
| SMT202000649T1 (it) | 2021-01-05 |
| PL3380487T3 (pl) | 2020-12-28 |
| US10617765B2 (en) | 2020-04-14 |
| HRP20201832T1 (hr) | 2021-01-08 |
| LT3380487T (lt) | 2020-12-28 |
| PT3380487T (pt) | 2020-10-29 |
| HUE052634T2 (hu) | 2021-05-28 |
| KR20180081610A (ko) | 2018-07-16 |
| US11213589B2 (en) | 2022-01-04 |
| KR102688003B1 (ko) | 2024-07-23 |
| EP3789395B1 (en) | 2025-08-27 |
| EP3380487B1 (en) | 2020-09-02 |
| EP3789395A1 (en) | 2021-03-10 |
| DK3380487T3 (da) | 2020-12-07 |
| CN108350025A (zh) | 2018-07-31 |
| JP2019503994A (ja) | 2019-02-14 |
| US20220160883A1 (en) | 2022-05-26 |
| ES2827776T3 (es) | 2021-05-24 |
| WO2017091568A1 (en) | 2017-06-01 |
| CN108350025B (zh) | 2023-02-21 |
| US20190351065A1 (en) | 2019-11-21 |
| EP3380487A1 (en) | 2018-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Koniev et al. | Developments and recent advancements in the field of endogenous amino acid selective bond forming reactions for bioconjugation | |
| Menegatti et al. | mRNA display selection and solid‐phase synthesis of Fc‐binding cyclic peptide affinity ligands | |
| JP7257457B2 (ja) | タンパク質のｐｅｇ化に用いるための添加物系 | |
| EP0113538A2 (en) | Protein sequencing method and reagent | |
| Fukuzumi et al. | Chemoselective cyclization of unprotected linear peptides by α-ketoacid–hydroxylamine amide-ligation | |
| AU2021209196B2 (en) | Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond | |
| EA039002B1 (ru) | Способ получения белка | |
| JP6667856B2 (ja) | 糖タンパク質の糖鎖遊離法 | |
| Arrigoni et al. | Morpholine Prevents the Formation of Aspartimide from β-allyl ester aspartic acid during Fmoc Cleavage in SPPS of Stapled Peptides | |
| Yon et al. | Protein folding in vitro and in the cellular environment | |
| Byun et al. | Preparation of polymer-bound pyrazolone active esters for combinatorial chemistry | |
| US20180245115A1 (en) | Method, kit and device for preparing glycoprotein sugar chain | |
| Neo et al. | Allylic amination of Passerini adducts. Application to the selective synthesis of chromone-substituted α-and γ-amino acid peptidic and retropeptidic units | |
| JP6237948B1 (ja) | 糖鎖を調製する方法 | |
| KR101692992B1 (ko) | 고리형 펩타이드의 사전 활성화 합성방법 및 이에 따라 합성된 고리형 펩타이드 | |
| Wan et al. | Automated Rapid Synthesis of High-Purity Head-to-Tail Cyclic Peptides via a Diaminonicotinic Acid Scaffold | |
| MacDonald | Site-specific modification of proteins with 2-pyridinecarboxaldehyde derivatives | |
| WO2020121071A1 (en) | Acylation process for preparation of n-substituted peptide | |
| JP2019167323A (ja) | 糖タンパク質精製方法および糖鎖を調製する方法 | |
| Carbonell | mRNA display selection and solid-phase synthesis of Fc-binding cyclic peptide affinity ligands |